Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. - Pinkle D; Cornils M; Dietterle A; Laqua A; Kurschies M; Heymann J; Funke E; Fanter P; Gupta DD; Reimer C; Mahachi DT; Gehlert CL; et al. (HemaSphere, 2026)